» Articles » PMID: 35242144

A Necroptosis-Related Prognostic Model of Uveal Melanoma Was Constructed by Single-Cell Sequencing Analysis and Weighted Co-Expression Network Analysis Based on Public Databases

Overview
Journal Front Immunol
Date 2022 Mar 4
PMID 35242144
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Uveal melanoma(UVM) is the most common intraocular malignancy and has a poor prognosis. The clinical significance of necroptosis(NCPS) in UVM is unclear.

Methods: We first identified necroptosis genes in UVM by single-cell analysis of the GSE139829 dataset from the GEO database and weighted co-expression network analysis of TCGA data. COX regression and Lasso regression were used to construct the prognostic model. Then survival analysis, immune microenvironment analysis, and mutation analysis were carried out. Finally, cell experiments were performed to verify the role of ITPA in UVM.

Result: By necroptosis-related prognostic model, UVM patients in both TCGA and GEO cohorts could be classified as high-NCPS and low-NCPS groups, with significant differences in survival time between the two groups (P<0.001). Besides, the high-NCPS group had higher levels of immune checkpoint-related gene expression, suggesting that they might be more likely to benefit from immunotherapy. The cell experiments confirmed the role of ITPA, the most significant gene in the model, in UVM. After ITPA was knocked down, the activity, proliferation, and invasion ability of the MuM-2B cell line were significantly reduced.

Conclusion: Our study can provide a reference for the diagnosis and treatment of patients with UVM.

Citing Articles

Machine Learning-Based Pathomics Model to Predict the Prognosis in Clear Cell Renal Cell Carcinoma.

Li X, Yang X, Yang X, Xie X, Rui W, He H Technol Cancer Res Treat. 2024; 23:15330338241307686.

PMID: 39703069 PMC: 11662324. DOI: 10.1177/15330338241307686.


Relationship between EZH2 expression and prognosis of patients with hepatocellular carcinoma using a pathomics predictive model.

Zhou X, Man M, Cui M, Zhou X, Hu Y, Liu Q Heliyon. 2024; 10(20):e38562.

PMID: 39640777 PMC: 11619983. DOI: 10.1016/j.heliyon.2024.e38562.


Development and validation of a radiomic prediction model for TACC3 expression and prognosis in non-small cell lung cancer using contrast-enhanced CT imaging.

Bai W, Zhao X, Ning Q Transl Oncol. 2024; 51:102211.

PMID: 39603208 PMC: 11635781. DOI: 10.1016/j.tranon.2024.102211.


Pathomic and bioinformatics analysis of clinical-pathological and genomic factors for pancreatic cancer prognosis.

Li Y, Pan L, Mugaanyi J, Li H, Li G, Huang J Sci Rep. 2024; 14(1):27769.

PMID: 39533091 PMC: 11557977. DOI: 10.1038/s41598-024-79619-1.


Machine Learning-enhanced Signature of Metastasis-related T Cell Marker Genes for Predicting Overall Survival in Malignant Melanoma.

Fan C, Li Y, Jiang A, Zhao R J Immunother. 2024; 48(3):97-108.

PMID: 39506915 PMC: 11875406. DOI: 10.1097/CJI.0000000000000544.


References
1.
Frank D, Vince J . Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2018; 26(1):99-114. PMC: 6294779. DOI: 10.1038/s41418-018-0212-6. View

2.
van Essen T, van Pelt S, Bronkhorst I, Versluis M, Nemati F, Laurent C . Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes. PLoS One. 2016; 11(10):e0164292. PMC: 5072555. DOI: 10.1371/journal.pone.0164292. View

3.
Xie J, Ruan S, Zhu Z, Wang M, Cao Y, Ou M . Database mining analysis revealed the role of the putative H/sugar transporter solute carrier family 45 in skin cutaneous melanoma. Channels (Austin). 2021; 15(1):496-506. PMC: 8331014. DOI: 10.1080/19336950.2021.1956226. View

4.
Rozeman E, Prevoo W, Meier M, Sikorska K, Van T, van de Wiel B . Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Res. 2020; 30(3):252-260. DOI: 10.1097/CMR.0000000000000653. View

5.
Wong R . Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011; 30:87. PMC: 3197541. DOI: 10.1186/1756-9966-30-87. View